John McConnell, MD
Pulmonary Disease · Louisville, KYNPI 1902831761
Payments from drug & device makers
Across 1,154 payments — averaging $3064.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1.6M
- Actelion Pharmaceuticals US, Inc.$625K
- Janssen Research & Development, LLC$314K
- Bayer$263K
- Actelion Pharmaceuticals, Ltd$236K
- United Therapeutics Corporation$202K
- plus $306K from 24 others
Across 1 payment — averaging $1159.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$1K
What the payments were for
- Consulting fees$125,25514%
- Speaking & faculty fees$595,53169%
- Travel & lodging$116,35013%
- Food & beverage$27,1103%
- Education$1980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 159 | $1,590,923 |
| Actelion Pharmaceuticals US, Inc. | 529 | $624,567 |
| Janssen Research & Development, LLC | 64 | $314,469 |
| Bayer | 168 | $262,918 |
| Actelion Pharmaceuticals, Ltd | 32 | $236,259 |
| United Therapeutics Corporation | 103 | $201,578 |
| Sumitomo Pharma America, Inc. | 8 | $149,727 |
| E.r. Squibb & Sons, L.L.C. | 8 | $86,014 |
| Pfizer | 7 | $32,074 |
| Novartis | 2 | $14,469 |
| Johnson & Johnson | 10 | $9,274 |
| Enzyvant Therapeutics, Inc. | 1 | $7,816 |
| Astellas Pharma US Inc | 3 | $2,457 |
| Mylan Specialty L.p. | 2 | $816 |
| Insmed, Inc. | 18 | $439 |
| Sandoz | 6 | $427 |
| Boehringer Ingelheim | 5 | $377 |
| AstraZeneca | 4 | $350 |
| GSK | 6 | $272 |
| Inari Medical, Inc. | 1 | $231 |
| Vero Biotech Inc. | 2 | $219 |
| La Jolla Pharmaceutical Company | 2 | $177 |
| Abbott | 1 | $139 |
| Genentech USA, Inc. | 7 | $124 |
| Chiesi USA, Inc. | 1 | $110 |
| Edwards Lifesciences | 1 | $108 |
| Liquidia Technologies, Inc. | 1 | $81 |
| Philips North America LLC | 1 | $73 |
| AbbVie | 1 | $18 |
| Grifols USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UPTRAVI$466,914
- OPSUMIT$397,550
- Adempas$150,626
- WINREVAIR$62,852
- REMODULIN$6,935
- VELETRI$4,725
- CRESEMBA$2,449
- BOSENTAN$1,465
- Yupelri$800
- TREPROSTINIL$276
- FLOWTRIEVER CATHETER, S$231
- CT THROMBECTOMY SYSTEM KIT$231
- TYVASO$213
- Genosyl$204
- CARDIOMEMS$139
- Arikayce$137
- FASENRA$123
- OFEV$122
- AREXVY$113
- All-In-One$112
How this compares
$3,536,522 in reported general payments places this provider in the 95th percentile of 226 pulmonary disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 946 | $11,971,909 |
| UptraviSelexipag | 476 | $10,681,793 |
| AdempasRiociguat | 610 | $8,612,895 |
| WinrevairSotatercept-Csrk | 238 | $3,930,503 |
| OfevNintedanib Esylate | 55 | $717,806 |
| OpsynviMacitentan/Tadalafil | 41 | $525,341 |
| Tyvaso DpiTreprostinil | 18 | $435,554 |
| Ambrisentan | 114 | $288,070 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 23 | $202,547 |
| LetairisAmbrisentan | 17 | $200,898 |
| AdcircaTadalafil | 38 | $153,785 |
| Orenitram ErTreprostinil Diolamine | 20 | $152,758 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 164 | $144,926 |
| GlassiaAlpha-1-Proteinase Inhibitor | 13 | $73,306 |
| RevatioSildenafil Citrate | 12 | $62,196 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Opsynvi | $624,567 | $23,179,0441,463 claims |
| BayerAdempas | $262,918 | $8,612,895610 claims |
| MerckWinrevair | $1,590,923 | $3,930,503238 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $377 | $777,865141 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $272 | $203,208290 claims |
| Grifols USA, LLCProlastin C | $14 | $202,54723 claims |
| United Therapeutics CorporationAdcirca | $201,578 | $153,78538 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $350 | $84,392144 claims |
| Johnson & JohnsonVeletri | $9,274 | $36,71512 claims |
| PfizerEliquis | $32,074 | $36,32751 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 226 pulmonary disease providers in Kentucky.
Other pulmonary disease in Louisville
- Sally SulimanLouisville$472K
- Mohamed SaadLouisville$440K
- David WinslowLouisville$431K
- Karim El-KershLouisville$379K
- Harold HallerLouisville$369K
- Samantha BaahLouisville$226K
- Lebnan SaadLouisville$105K
- Josephine MeiLouisville$101K
- Tanya WieseLouisville$75K
- Rodrigo CavallazziLouisville$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.